Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action

BACKGROUND: Bispecific T cell engaging antibodies (TEAs) with one arm targeting a cancer antigen and another arm binding to CD3 have demonstrated impressive efficacy in multiple clinical studies. However, establishing a safety/efficacy balance remains challenging. For instance, some TEAs have severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Wenyan, Dong, Jianbo, Gallolu Kankanamalage, Sachith, Titong, Allison, Shi, Jiadong, Jia, Zhejun, Wang, Bo, Huang, Cai, Zhang, Jing, Lin, Jun, Kan, Steven Z, Han, Shuhua, Zhou, Joe, Liu, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597964/
https://www.ncbi.nlm.nih.gov/pubmed/34805746
http://dx.doi.org/10.1093/abt/tbab024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597964/
https://www.ncbi.nlm.nih.gov/pubmed/34805746
http://dx.doi.org/10.1093/abt/tbab024

Ejemplares similares